Fujifilm Diosynth to establish viral vector manufacturing in Boston

By The Science Advisory Board staff writers

Contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies will establish a new process development and manufacturing facility in Watertown, MA, near Boston, for viral vectors and advanced therapies.

Funded via a $40 million investment by Fujifilm Corporation, the new facility will be the third location for viral vector CDMO services provided by Fujifilm Diosynth Biotechnologies, according to the company. Process development operations are slated to commence in the fall of 2021, with contract manufacturing services for early-phase clinical trials expected to begin at the facility in the fall of 2023.

The facility will house experimental and analytical equipment for viral vector and advanced therapy process development, the firm said.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: